KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI-1607, YERVOY 5 mg/ml concentrate for solution for infusion clinical trials

An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

This study is testing new combinations of medicines for advanced melanoma, a type of skin cancer that has spread or can't be removed by surgery. It looks at how safe the medicines are and how well they shrink tumours.